Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02535247 · BASELINE

Baseline characteristics

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma · Source last updated 2022-07-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      17
    2. group Id
      BG001
      value
      0
    3. group Id
      BG002
      value
      17
    units
    Participants
groups
  1. description
    MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
    id
    BG000
    title
    Treatment
  2. description
    MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
    id
    BG001
    title
    Combination
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          18
          upper Limit
          88
          value
          71
        2. group Id
          BG002
          lower Limit
          18
          upper Limit
          88
          value
          71
      denoms
      1. counts
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          17
        units
        Participants
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          9
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          9
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          8
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          8
        title
        Male
      denoms
      1. counts
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          17
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG002
          value
          0
      denoms
      1. counts
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    population Description
    Race and Ethnicity were not collected from any participant.
    title
    Race and Ethnicity Not Collected
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          17
        2. group Id
          BG002
          value
          17
      denoms
      1. counts
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          17
        units
        Participants
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
Study did not progress to portion with combination of pembrolizumab and copanlisib
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      17
    2. group Id
      BG001
      value
      0
    3. group Id
      BG002
      value
      17
    units
    Participants
groups
  1. description
    MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
    id
    BG000
    title
    Treatment
  2. description
    MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
    id
    BG001
    title
    Combination
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          18
          upper Limit
          88
          value
          71
        2. group Id
          BG002
          lower Limit
          18
          upper Limit
          88
          value
          71
      denoms
      1. counts
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          17
        units
        Participants
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          9
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          9
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          8
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          8
        title
        Male
      denoms
      1. counts
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          17
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG002
          value
          0
      denoms
      1. counts
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    population Description
    Race and Ethnicity were not collected from any participant.
    title
    Race and Ethnicity Not Collected
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          17
        2. group Id
          BG002
          value
          17
      denoms
      1. counts
        1. group Id
          BG000
          value
          17
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          17
        units
        Participants
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
Study did not progress to portion with combination of pembrolizumab and copanlisib

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice